A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

HER2-positive breast cancer accounts for 20–30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of trastuzumab in 1998 has significantly improved ...

a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumour cells and the CD3 receptor on T-cells, developed in partnership with ...

The results above have elucidated how GP73 is activated in cancer cells; furthermore ... Further pieces of evidence prove that, as well as GP73/EGFR interaction, MMP-2 and MMP-7 interact with the ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and ...

and the immediate implications for clinical practice and research Resistance to anti-EGFR therapy is a clinical issue for patients with advanced head and neck cancers. Here, the authors show that ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

The Indian government has decided to exempt customs duty on 36 life-saving drugs to enhance access to essential treatments ...

Genetics is key to the development of cancer and also in the progression. Some inherited mutations confer a susceptibility to ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...